Q: Is Ventamin Light Up suitable for pregnant or breastfeeding women
With the lack of any FDA regulation or oversight of peptides, anyone can get in the business
Features a lightweight, rapidly absorbing formula that prepares the skin for subsequent treatment steps without leaving a sticky finish
We use cyanocobalamin by default, the form of B12 with the longest clinical history, the most extensive research support, and the consistent potency needed for repeated treatments
What the FDA will review (and when) According to the FDA Law Blog breakdown, the FDA has scheduled the Pharmacy Compounding Advisory Committee (PCAC) to review peptides for possible inclusion on the Section 503A bulks list on two timelines: PCAC meeting: July 2324, 2026 July 23: BPC-157, KPV, TB-500, MOTs-C (FDA Law Blog) July 24: Emideltide (DSIP), Semax, Epithalon (FDA Law Blog) Second PCAC meeting: before the end of February 2027 GHK-Cu, Melanotan II, Cathelicidin (LL-37), Dihexa acetate, PEG-MGF (FDA Law Blog) Well update this post as the FDA releases briefing packets, conflict-of-interest disclosures, and voting questions closer to the meeting
Juliet took me through each step and explained to me what to expect
